BioSpace News Archive

Tango Therapeutics, Inc. today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers.

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer.

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that the company has entered into an agreement to acquire EryDel SpA.

Labcorp announced today it now offers menopause testing through its Labcorp OnDemand digital health platform.

Quipt Home Medical Corp. today announced that members of its management team will host a webcasted fireside chat and participate in 1x1 meetings at the 43rd Annual Canaccord Growth Conference on August 9th - 10th, 2023.

Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement.

HanchorBio Inc.announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101.

Talis Biomedical Corporation today announced that it received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share.

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that Health Canada, the Canadian government’s regulatory agency, has approved IceCure’s ProSense System, disposable cryoprobes.

Nectero Medical today announced that the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance for the company to initiate a prospective, multi-center, randomized clinical trial (the stAAAble Study) to evaluate the safety and efficacy of the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) in patients with infrarenal abdominal aortic aneurysms (AAAs), maximum diameter 3.5 – 5.0cm.